Stockscreener 앱 받기
41.85
0.57%
-0.24
시간 외 거래:
41.85
전일 마감가:
$42.09
열려 있는:
$42.39
하루 거래량:
735.81K
Relative Volume:
1.37
시가총액:
$2.87B
수익:
$35.93M
순이익/손실:
$-244.56M
주가수익비율:
-11.13
EPS:
-3.76
순현금흐름:
$-157.31M
1주 성능:
-2.29%
1개월 성능:
-2.52%
6개월 성능:
-22.41%
1년 성능:
+61.71%
1일 변동 폭
$41.59
$43.26
1주일 범위
$41.59
$45.25
52주 변동 폭
$25.83
$61.61
Merus N V Stock (MRUS) Company Profile
명칭
Merus N V
전화
31 030 253 8800
주소
YALELAAN 62, 3584 CM UTRECHT
MRUS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRUS
Merus N V
|
41.85 | 2.87B | 35.93M | -244.56M | -157.31M | -3.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Merus N V Stock (MRUS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-21 | 개시 | Goldman | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-03-28 | 개시 | Truist | Buy |
| 2024-03-04 | 재확인 | Needham | Buy |
| 2023-11-02 | 개시 | Canaccord Genuity | Buy |
| 2023-08-21 | 개시 | TD Cowen | Outperform |
| 2022-08-02 | 개시 | Stifel | Buy |
| 2022-02-11 | 개시 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Needham | Buy |
| 2021-11-17 | 재개 | Guggenheim | Buy |
| 2021-06-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-04-08 | 개시 | William Blair | Outperform |
| 2021-03-16 | 개시 | SVB Leerink | Outperform |
| 2020-06-26 | 개시 | H.C. Wainwright | Buy |
| 2020-05-27 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-20 | 재개 | Guggenheim | Buy |
| 2019-06-28 | 개시 | ROTH Capital | Buy |
| 2019-04-12 | 재개 | Guggenheim | Buy |
| 2019-04-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-03-27 | 개시 | Berenberg | Buy |
| 2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-03-21 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-12-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2016-11-07 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-06-13 | 개시 | Citigroup | Buy |
| 2016-06-13 | 개시 | Guggenheim | Buy |
| 2016-06-13 | 개시 | Wedbush | Outperform |
모두보기
Merus N V 주식(MRUS)의 최신 뉴스
Comparing Merus (NASDAQ:MRUS) & Tenax Therapeutics (NASDAQ:TENX) - Defense World
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC - GlobeNewswire
Merus Launches Phase 2 Trial for Novel Cancer Drug Petosemtamab in Advanced Colorectal Cancer - StockTitan
Merus N.V.'s SWOT analysis: antibody innovator's stock faces pivotal year - Investing.com
Franklin Resources Inc. Acquires 150,341 Shares of Merus (NASDAQ:MRUS) - MarketBeat
(MRUS) Technical Data - Stock Traders Daily
Lord Abbett & CO. LLC Purchases 328,316 Shares of Merus (NASDAQ:MRUS) - MarketBeat
Janus Henderson Group PLC Has $944,000 Stake in Merus (NASDAQ:MRUS) - MarketBeat
Merus (NASDAQ:MRUS) Holdings Lifted by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight - Insider Monkey
Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy - Insider Monkey
Merus (NASDAQ:MRUS) Stock Price Expected to Rise, Citigroup Analyst Says - MarketBeat
Wellington Management Group LLP Grows Position in Merus (NASDAQ:MRUS) - MarketBeat
Merus’ (MRUS) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World
Citi raises Merus target to $97 on positive trial data By Investing.com - Investing.com South Africa
Citi raises Merus target to $97 on positive trial data - Investing.com
Needham & Company LLC Reaffirms "Buy" Rating for Merus (NASDAQ:MRUS) - MarketBeat
The Manufacturers Life Insurance Company Has $2.56 Million Stock Position in Merus (NASDAQ:MRUS) - Defense World
Positive early data on Merus’ petosemtamab - The Pharma Letter
The Manufacturers Life Insurance Company Sells 11,463 Shares of Merus (NASDAQ:MRUS) - MarketBeat
Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC - GlobeNewswire Inc.
Zwischenergebnisse der Monotherapie mit Petosemtamab von - GlobeNewswire
US FDA approves Merus' therapy to treat lung, pancreatic cancers - MSN
Merus’ Petosemtamab Monotherapy Interim Data Continues to - GlobeNewswire
Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC - The Manila Times
Merus's Cancer Drug Shows 36% Response Rate in Head & Neck Cancer Trial, Including Complete Responses - StockTitan
FY2025 Earnings Forecast for Merus Issued By Leerink Partnrs - Defense World
Merus Scores Its First FDA Approval For Lung Cancer Drug - Benzinga
First for Merus, first for NRG1+ cancers: US FDA approves Bizengri - BioWorld Online
Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers - Yahoo Finance
Jim Cramer: This Health Care Stock Is 'Very, Very Speculative' - Benzinga
A first for Merus’ Bizengri with FDA nod - The Pharma Letter
Trend Tracker for (MRUS) - Stock Traders Daily
Guggenheim Reiterates Buy Rating for Merus (NASDAQ:MRUS) - Defense World
William Blair Has Bearish Forecast for Merus Q3 Earnings - Defense World
US drug body approves Merus' therapy for lung, pancreatic cancer patients - Business Standard
Cramer's Lightning Round: Merus is 'very speculative' - CNBC
Merus Gets FDA Approval for Bizengri Treatment - Marketscreener.com
Merus Announces FDA Approval of BIZENGRI® - GlobeNewswire
Merus Secures FDA Approval for Groundbreaking NRG1+ Cancer Treatment BIZENGRI - StockTitan
Merus’ zenocutuzumab-zbco granted accelerated approval by FDA - TipRanks
Merus price target lowered to $109 from $111 at Guggenheim - Yahoo Finance
Merus's SWOT analysis: biotech stock's potential in antibody therapies By Investing.com - Investing.com South Africa
Merus's SWOT analysis: biotech stock's potential in antibody therapies - Investing.com
Merus shares target cut, buy rating held on PTx deal By Investing.com - Investing.com Canada
Merus shares target cut, buy rating held on PTx deal - Investing.com
HighVista Strategies LLC Reduces Stock Position in Merus (NASDAQ:MRUS) - MarketBeat
Merus's SWOT analysis: innovative antibody stock shows promise amid clinical trials - Investing.com
BMO maintains $95 target on Merus, positive on trial data By Investing.com - Investing.com Canada
Merus licenses cancer drug to Partner Therapeutics for US market By Investing.com - Investing.com Canada
Merus N V (MRUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Merus N V 주식 (MRUS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Shuman Harry | VP Controller, PAO |
Aug 20 '24 |
Sale |
54.00 |
2,500 |
135,000 |
7,002 |
| Silverman Peter B. | COO & GC |
Jun 27 '24 |
Option Exercise |
17.94 |
10,000 |
179,400 |
10,000 |
| Silverman Peter B. | COO & GC |
Jun 27 '24 |
Sale |
60.00 |
10,000 |
600,000 |
0 |
| Silverman Peter B. | COO & GC |
Jun 17 '24 |
Option Exercise |
24.36 |
62,000 |
1,510,280 |
62,000 |
| Silverman Peter B. | COO & GC |
Jun 17 '24 |
Sale |
56.52 |
62,000 |
3,504,178 |
0 |
| Shuman Harry | VP Controller, PAO |
Jun 12 '24 |
Sale |
57.84 |
7,300 |
422,232 |
7,002 |
| Shuman Harry | VP Controller, PAO |
Jun 10 '24 |
Sale |
53.22 |
1,000 |
53,224 |
7,002 |
| Shuman Harry | VP Controller, PAO |
Jun 04 '24 |
Sale |
52.89 |
6,000 |
317,354 |
7,002 |
2.88%
2.65%
자본화:
|
볼륨(24시간):